Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMAVangelis Karalis, Panos Macheras, Mira Symillides|Pharmaceutical Research|2011Cited by 68
Bioavailability and Bioequivalence: Focus on Physiological Factors and VariabilityVangelis Karalis, Vinod P. Shah, Panos Macheras et al.|Pharmaceutical Research|2008Cited by 64
Michaelis-Menten Kinetics under Spatially Constrained Conditions: Application to Mibefradil PharmacokineticsKosmas Kosmidis, Panos Macheras, Panos Argyrakis et al.|Biophysical Journal|2004Cited by 42
Novel Scaled Average Bioequivalence Limits Based on GMR and Variability ConsiderationsVangelis Karalis, Panos Macheras, Mira Symillides|Pharmaceutical Research|2004Cited by 32
Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off propertiesVangelis Karalis, Mira Symillides, Panos Macheras|European Journal of Pharmaceutical Sciences|2005Cited by 31